Literature DB >> 21622972

Wax moth larva (Galleria mellonella): an in vivo model for assessing the efficacy of antistaphylococcal agents.

Andrew P Desbois1, Peter J Coote.   

Abstract

OBJECTIVES: To investigate whether the wax moth larva, Galleria mellonella, is a suitable host for assessing the in vivo efficacy of antistaphylococcal agents against Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) infections.
METHODS: Wax moth larvae were infected with increasing doses of S. aureus to investigate the effect of inoculum size on larval survival. In addition, infected wax moth larvae were treated with daptomycin, penicillin or vancomycin to examine whether these agents were effective against S. aureus and MRSA infections in vivo.
RESULTS: Increasing inoculum doses of live S. aureus cells resulted in greater larval mortality, but heat-killed bacteria and cell-free culture filtrates had no detrimental effects on survival. Larval mortality rate also depended on the post-inoculation incubation temperature. After larvae were infected with S. aureus, larval survival was enhanced by administering the antistaphylococcal antibiotics daptomycin or vancomycin. Larval survival increased with increasing doses of the antibiotics. Moreover, penicillin improved survival of larvae infected with a penicillin-susceptible methicillin-susceptible S. aureus (MSSA) strain, but it was ineffective at similar doses in larvae infected with MRSA (penicillin resistant). Daptomycin and vancomycin were also effective when administered to the larvae prior to infection with bacteria.
CONCLUSIONS: This is the first report to demonstrate that antibiotics are effective in the wax moth larva model for the treatment of infections caused by Gram-positive bacteria. The new wax moth larva model is a useful preliminary model for assessing the in vivo efficacy of candidate antistaphylococcal agents before proceeding to mammalian studies, which may reduce animal experimentation and expense.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622972     DOI: 10.1093/jac/dkr198

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  74 in total

1.  Activity of a novel protonophore against methicillin-resistant Staphylococcus aureus.

Authors:  Nagendran Tharmalingam; Elamparithi Jayamani; Rajmohan Rajamuthiah; Dawilmer Castillo; Beth Burgwyn Fuchs; Michael J Kelso; Eleftherios Mylonakis
Journal:  Future Med Chem       Date:  2017-08-03       Impact factor: 3.808

2.  All models are wrong, but some are useful: Averting the 'microbial apocalypse'.

Authors:  Siouxsie Wiles
Journal:  Virulence       Date:  2015       Impact factor: 5.882

3.  Tedizolid is a promising antimicrobial option for the treatment of Staphylococcus aureus infections in cystic fibrosis patients.

Authors:  Melanie Roch; Maria Celeste Varela; Agustina Taglialegna; Adriana E Rosato
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

4.  Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.

Authors:  Regina Fernandez; Liliana I Paz; Roberto R Rosato; Adriana E Rosato
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

5.  Establishment and Validation of Galleria mellonella as a Novel Model Organism To Study Mycobacterium abscessus Infection, Pathogenesis, and Treatment.

Authors:  Michal Meir; Tatyana Grosfeld; Daniel Barkan
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

6.  Biofilm Inhibitor Taurolithocholic Acid Alters Colony Morphology, Specialized Metabolism, and Virulence of Pseudomonas aeruginosa.

Authors:  Alanna R Condren; Lisa Juliane Kahl; Gabriela Boelter; George Kritikos; Manuel Banzhaf; Lars E P Dietrich; Laura M Sanchez
Journal:  ACS Infect Dis       Date:  2020-01-03       Impact factor: 5.084

7.  A novel point mutation promotes growth phase-dependent daptomycin tolerance in Staphylococcus aureus.

Authors:  Lukas Mechler; Alexander Herbig; Kerstin Paprotka; Martin Fraunholz; Kay Nieselt; Ralph Bertram
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

8.  Raf-kinase inhibitor GW5074 shows antibacterial activity against methicillin-resistant Staphylococcus aureus and potentiates the activity of gentamicin.

Authors:  Tatiana Johnston; Gabriel Lambert Hendricks; Steven Shen; Roy Fangxing Chen; Bumsup Kwon; Michael John Kelso; Wooseong Kim; Beth Burgwyn Fuchs; Eleftherios Mylonakis
Journal:  Future Med Chem       Date:  2016-09-21       Impact factor: 3.808

9.  Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications.

Authors:  A Forastiero; A C Mesa-Arango; A Alastruey-Izquierdo; L Alcazar-Fuoli; L Bernal-Martinez; T Pelaez; J F Lopez; J O Grimalt; A Gomez-Lopez; I Cuesta; O Zaragoza; E Mellado
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

10.  β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.

Authors:  Shrenik Mehta; Christopher Singh; Konrad B Plata; Palas K Chanda; Arundhati Paul; Sarah Riosa; Roberto R Rosato; Adriana E Rosato
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.